🚀 Clinical Trials - Recent Developments
Recent clinical trials have shown promising results in various fields of medicine. This article summarizes key findings from recent trials.
Key Points:
• Teclistamab + daratumumab (TRIMM-2, phase 1b) in RRMM showed an ORR of 68.9% with a median PFS of 26.3mo.
• The study also reported a high rate of grade 3/4 TEAEs, leading to the stopping of a fixed-dose cohort.
• Harmoni 2 OS Press release showed an OS benefit, challenging Keytruda's dominance in the market.
• Daraxonrasib's NSCLC data showed an ORR of 35% overall, with a median PFS of 8.3mo and a median OS of 16mo.
• The study also reported a high rate of rash and diarrhea, with 25% of patients experiencing grade 3/4 TRAEs.
🔗 Resources:
• Original post ↗ - Original source
• KolPulseAI ↗ - AI-powered clinical trial insights
• Harmoni 2 OS Press release ↗ - OS benefit in NSCLC
• Daraxonrasib's NSCLC data ↗ - NSCLC trial results
• FDA Memorandum ↗ - FDA's override of primary clinical review team's recommendation
🚀 Longevity Research - PROSPR Program
The PROSPR program is testing whether changes in intrinsic capacity can help measure treatment benefits within a few years. This includes mobility, cognitive function, and other factors.
Key Points:
• The PROSPR program is a key initiative in longevity research, aiming to measure treatment benefits within a few years.
• The program includes mobility, cognitive function, and other factors to assess intrinsic capacity.
• The study aims to provide a more accurate measure of treatment benefits, which can take decades to show.
🔗 Resources:
• Original post ↗ - PROSPR program details
• ARPA_H ↗ - Agency for Research on Proving Research
🚀 Clinical Trials - AI-Human Collaboration
AI-human collaboration has shown promising results in clinical trials, with 37 amended radiology reports and 22 multidisciplinary team escalations.
Key Points:
• AI-human collaboration led to 37 amended radiology reports and 22 multidisciplinary team escalations.
• The study showed that AI can help the expert miss fewer things, making it incredibly valuable in clinical care.
• The study highlights the potential of AI-human collaboration in clinical trials.
🔗 Resources:
• Original post ↗ - AI-human collaboration in clinical trials
• Meet Augustai ↗ - AI researcher
🚀 Clinical Trials - HistoPLUS
HistoPLUS is a peer-reviewed, open-access journal that has published a study on H&E cell features alone predicting FGFR3 mutation status in bladder cancer.
Key Points:
• HistoPLUS published a study on H&E cell features alone predicting FGFR3 mutation status in bladder cancer.
• The study showed that H&E cell features alone predicted FGFR3 mutation status with an AUC of 0.80.
• The study highlights the potential of HistoPLUS in clinical trials.
🔗 Resources:
• Original post ↗ - HistoPLUS study details
• OwkinScience ↗ - AI-powered clinical trial insights
🚀 Clinical Trials - HD-tDCS Study
A pre-registered HD-tDCS study found that right cathodal DLPFC stimulation increased effort-related cardiac reactivity during a mental concentration task, with effects observed only in women.
Key Points:
• The study found that right cathodal DLPFC stimulation increased effort-related cardiac reactivity during a mental concentration task.
• The effects were observed only in women, highlighting the potential of HD-tDCS in clinical trials.
• The study highlights the potential of HD-tDCS in treating neurological disorders.
🔗 Resources:
• Original post ↗ - HD-tDCS study details
• Neuroelectrics ↗ - Neurostimulation company
